XOMA Royalty Corp
seralutinib
PAH
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for seralutinib in PAH are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“In February 2026, Gossamer Bio announced topline results from the Phase 3 PROSERA clinical trial evaluating seralutinib for the treatment of PAH 7 • Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) ”